CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
CG Oncology has raised $238.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
CG Oncology's investors include RA Capital Management, Janus Henderson Investors, TCG Crossover, Foresite Capital, Decheng Capital.
CG Oncology is headquartered in Irvine, United States.
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
CG Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CG Oncology — Funding & Investors." VCBacked, December 12, 2024, https://www.vcbacked.co/company/cg-oncology. Accessed September 30, 2026.
VCBacked. (2024). CG Oncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cg-oncology
{{cite web |title=CG Oncology — Funding & Investors |url=https://www.vcbacked.co/company/cg-oncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated